New research reveals GLP-1 drugs like Ozempic may reduce stroke risk and improve recovery. At the 22nd Annual Meeting of the ...

Six months ago, I took a leap into the unknown, writes DONAL MACINTYRE. After tipping the scales the other way, here I reveal ...

GLP-1 RAs are associated with reduced type 2 diabetes mellitus (T2DM)-related dementia risk compared with metformin.

GLP-1 drugs may reduce asthma symptoms in obese adults, offering a steroid-free alternative to treatment. The study includes ...

Exercising for just one minute a day, rather than gruelling stints at the gym could be the key to living longer, protecting ...

WEIGHT loss jabs could help control asthma symptoms in obese people, a study suggests – and it’s not just about losing weight ...

Eating disorder centers are facing an influx of people with weight-loss prescriptions. Experts say doctors are ...

GLP-1 drugs like Ozempic have already become a game-changer for obesity and diabetes. But new research shows they may also ...

Li, Huang, and Sirota chose 2 cancer drugs out of the top 5 drug candidates for laboratory testing. They predicted one drug, ...

A new international study reveals that GLP-1 receptor agonists—commonly used for weight loss—may significantly reduce the risk of dementia in people with type 2 diabetes, outperforming metformin.

Common medicines, including diabetes, cancer, and antiviral drugs, may offer new hope in slowing dementia. UK researchers, including a team from the University of Cambridge, have uncovered strong ...

GLP-1s - which mimic the effects of the hormone that stimulates insulin release, suppressing glucagon, and slowing gastric emptying - also have a range of other benefits.